Table 3 Clinicopathological features in relation to disease-free-survival (n = 447)

Age (> 56 vs. ≤ 56)

0.67

0.45–1.24

0.200

0.51

0.25–0.98

0.043

Tumor size (> 17 mm vs. ≤ 17 mm)

3.72

1.95–7.56

< 0.001

3.24

1.64–6.76

< 0.001

Lymph node metastasis (positive vs. negative)

4.93

2.68–9.29

< 0.001

4.24

2.23–8.24

< 0.001

Histology (NST vs. special type)

0.98

0.42–2.86

0.973

Tumor grade (high vs. low/intermediate)

0.89

0.43–1.73

0.740

0.88

0.41–1.75

0.725

Ki67 LI (> 48% vs. ≤ 48%)

0.91

0.46–1.81

0.790

ER (positive vs. negative)

0.58

0.32–1.07

0.082

0.43

0.22–0.83

0.012

PgR (positive vs. negative)

0.84

0.45–1.55

0.582

HER2 (2 + FISH + vs. 3+)

1.08

0.37–2.52

0.866

1.10

0.36–2.75

0.855

Administration of chemotherapy (yes vs. no)

0.92

0.48–1.88

0.814

0.57

0.29–1.21

0.139

Administration of anti-HER2 therapy (yes vs. no)

1.06

0.54–2.27

0.873